• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey

    2021-04-17 06:55:16NataliaSousaFreitasQueirozFabioVieiraTeixeiraMarinaPamponetMottaLilianaAndradeChebliAdrianoAkiraFerreiraHinoCamilladeAlmeidaMartinsAbelBotelhoQuaresmaAlexandreAugustodePauladaSilvaAdersonOmarMouraoCintraDamiaoRogerioSaa
    World Journal of Gastroenterology 2021年12期

    Natalia Sousa Freitas Queiroz, Fabio Vieira Teixeira, Marina Pamponet Motta, Liliana Andrade Chebli, Adriano Akira Ferreira Hino, Camilla de Almeida Martins, Abel Botelho Quaresma, Alexandre Augusto de Paula da Silva, Aderson Omar Mourao Cintra Damiao, Rogerio Saad-Hossne, Paulo Gustavo Kotze

    Abstract

    BACKGROUND Coronavirus disease 2019 (COVID-19 ) pandemic is still evolving globally, and Brazil is currently one of the most affected countries. It is still debated whether statement: The study was approved by the GEDIIB ethical review board under the protocol No. 002 /2020 on October 28 th,2020 . Informed consent was waived because the survey recruitment was self-selective. In addition, data were de-identified.Individual participant data were not published, which maintained confidentiality in all steps of study analysis. This study was conducted in compliance with regulations stated in the 1975 Declaration of Helsinki.patients with inflammatory bowel disease (IBD) are at a higher risk for developing COVID-19 or its complications.

    AIM To assess geographical distribution of IBD patients at the highest risk and correlate these data with COVID-19 mortality rates in Brazil.

    METHODS The Brazilian IBD Study Group (Grupo de Estudos da Doen?a Inflamatória Intestinal do Brasil) developed a web-based survey adapted from the British Society of Gastroenterology guidelines. The included categories were demographic data and inquiries related to risk factors for complications from COVID-19 . Patients were categorized as highest, moderate or lowest individual risk. The Spearman correlation test was used to identify any association between highest risk and mortality rates for each state of the country.

    RESULTS A total of 3568 patients (65 .3 % females) were included. Most participants were from the southeastern and southern regions of Brazil, and 84 .1 % were using immunomodulators and/or biologics. Most patients (55 .1 %) were at moderate risk, 23 .4 % were at highest risk and 21 .5 % were at lowest risk of COVID-19 complications. No association between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified in different Brazilian states (r = 0 .146 , P = 0 .467 ).

    CONCLUSION This study indicates a distinct geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country, which may reflect contrasting socioeconomic, educational and healthcare aspects. No association between high risk of IBD and COVID-related mortality rates was identified.

    Informed consent statement: As this is a cross-sectional survey analyzing anonymous data, and information used derived from an unidentified database, informed consent from each individual was waived.

    Conflict-of-interest statement:Kotze PG reports grants and personal fees from Takeda, grants and personal fees from Pfizer,personal fees from Janssen,personal fees from Abbvie,personal fees from Novartis,personal fees from Ferring, outside the submitted work.

    Data sharing statement: Study data are de-identified. Data are provided only for the approved study. Data will not be shared with anyone outside of the named members of the investigator team.

    STROBE statement: The authors have read the STROBE Statementchecklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

    Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4 .0 )license, which permits others to distribute, remix, adapt, build upon this work non-commercially,and license their derivative works on different terms, provided the original work is properly cited and

    Key Words: Crohn’s disease; Colitis, Ulcerative; COVID-19 ; Inflammatory bowel disease;Brazil

    INTRODUCTION

    The World Health Organization declared coronavirus disease 2019 (COVID-19 ) a pandemic on March 11 , 2020 . Although many countries are already registering a reduction in the incidence of infections and starting vaccination programs, Brazil is the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4 .0 /currently one of the leaders in the world on a daily basis for both numbers of new cases and deaths. As of November 28 , 2020 , we have confirmed 6238250 infected patients and 171998 COVID-related deaths[1].

    Available data suggests that patients with inflammatory bowel disease (IBD) are not at a higher risk for severe acute respiratory syndrome coronavirus-2 infection or the development of COVID-19 complications[2 ]. Moreover, the evolution of COVID-19 does not seem to be worse in patients with IBD, irrespective of their treatment. A recent analysis of 525 IBD patients from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease revealed that increasing age, comorbidities and corticosteroids are associated with worse outcomes of COVID-19 and that treatment with tumor necrosis factor inhibitors (TNFi) was not associated with severe COVID-19 . The number of reported patients exposed to other medical options was insufficient to drive conclusions regarding risk for severe outcomes in this population[3]. Recently, another report from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease registry aimed to evaluate the association of IBD medications and their combinations on the risk of adverse COVID-19 outcomes. Based on data from over 1400 IBD patients, it was demonstrated that the combination of thiopurines with TNFi and thiopurine monotherapy are associated with a significantly increased risk of severe COVID-19 as compared with TNFi monotherapy. Anti-interleukins and anti-integrins were not associated with a significantly different risk than TNFi monotherapy[4]. Regardless of the risk of IBD medications, it is noteworthy that maintaining patients in remission with steroid-sparing treatments may be crucial during the pandemic period.

    As the effect of immunosuppressive agents in IBD patients remains unclear during the pandemic, the British Society of Gastroenterology has issued guidance on risk stratification for IBD patients depending on medications in use, age, comorbidities and other risk factors[5]. Patients at highest risk for COVID-related complications are those who have a comorbidity and/or are over 70 -years-old and are on any immunosuppressant therapy for IBD. Those of any age that are receiving ≥ 20 mg of prednisolone, undergoing new induction therapy with biologics and immunomodulators (combination therapy) within 6 wk with moderate to severe active disease with short gut syndrome or patients requiring parenteral nutrition are also considered at highest risk for severe COVID-19 outcomes. Patients receiving biological therapy,thiopurines, calcineurin inhibitors, Janus kinase inhibitors or combination therapy are stratified as moderate risk and the remaining IBD patients as lowest risk. Depending on the risk stratification, recommendations can be suggested. Patients at highest risk are advised to self-isolate, while patients at moderate risk or lowest risk should follow strict social distancing or social distancing as for the general population, respectively.Specific guidance on instructions for self-isolation (shielding education) and social distancing measures to reduce spread of the disease within the population and to protect vulnerable groups has been recently issued[6].

    In order to identify Brazilian IBD patients who could be at high risk for COVID-19 complications, a taskforce group from the Brazilian IBD Study Group (Grupo de Estudos da Doen?a Inflamatória Intestinal do Brasil, GEDIIB) developed an anonymous web-based survey that allows self-identification risk assessment adapted from the British Society of Gastroenterology guidelines. Through a decision tree,patients were self-identified into different groups according to their risk of developing COVID-19 complications and received updated information according to their respective group (Table 1 ).

    Currently, Brazil still has one of the fastest growing severe acute respiratory syndrome coronavirus-2 outbreaks in the world with one of the highest mortality rates, just behind the United States. Given that a higher absolute number of deaths in the context of an epidemic may reflect a strained healthcare system and economy,mapping IBD patients at highest risk for COVID-19 complications could help public authorities to delineate protection strategies to this possibly vulnerable population.Our study aimed to assess geographical distribution of IBD patients at highest risk and correlate these data with COVID-19 mortality rates in different states of Brazil.

    MATERIALS AND METHODS

    Data collection and participants

    The GEDIIB COVID taskforce members in collaboration with experts in the field developed a questionnaire and established a decision tree to evaluate IBD patients pertaining to their risk of serious complications from COVID-19 . The national surveywas available on the website (diicovid.com.br). Data was collected from April 14 , 2020 to June 2 , 2020 . An informative article concerning this survey was posted at the official GEDIIB website, official mailing lists for patients and in national IBD patient association communication medias. All identified erroneous reports were removed for higher accuracy of the data.

    Table 1 Recommendations for inflammatory bowel disease patients according to their risk level

    The questionnaire consisted of fourteen questions (Supplementary Table 1 ). The included categories were demographic data (state and city of residence in Brazil, age,sex, smoking status) and questions related to the risk factors for complications from COVID-19 in IBD populations according to current previously published guidance[5 ,6].The questions included IBD medications in use, self-reported comorbidities(hypertension, diabetes, cardiovascular disease and chronic pulmonary disease) and abdominal surgery for IBD performed in the past 30 d. Through a decision tree,patients were categorized as highest, moderate or lowest individual risk for the potential to develop serious complications from COVID-19 and received updated recommendations according to their risk level. Respondents were distributed according to their respective domiciliary states.

    States of the national federation with a proportion of respondents at the highest risk for COVID-19 infection that were higher than the median rate of the overall country were considered for the analysis. Additionally, states with higher COVID-related cumulative mortality rates than the median of the country (as of June 2 , 2020 , the last available date of the survey) were also grouped. A possible correlation of these findings would suggest if there could be any coincidental relation between highest risk for COVID-19 complications and mortality in the same states.

    Statistical analysis

    Demographic and clinical characteristics of the study population were summarized by descriptive statistics. Categorical variables were expressed as absolute counts and percentages and continuous variables as means and standard deviations. Data was presented initially for the total study population. Thereafter, it was organized according to the five Brazilian regions and respective states to evaluate their geographical distribution. The frequencies of patients using each therapeutic IBD regimen in combination with oral steroids were analyzed as subcategories.

    Categorical variables were compared using a Chi-squared test, and continuous data was analyzed using Student’s t-test. A two-tailed P value of 0 .05 was used for statistical significance. The Spearman correlation test was performed to study a possible correlation between the proportion of highest risk patients and COVID-19 cumulative mortality in states with higher rates compared with the median national cutoffs for each variable. Data was exported and analyzed in SPSS Statistics 23 (IBM Corporation, Armonk, NY, United States).

    Data regarding COVID-19 cumulative death rates from March 3 (first death registered in Brazil) to June 2 were obtained from the Brazilian Ministry of Health COVID-19 website, (https://covid.saude.gov.br/). We computed the COVID-19 mortality per 100000 people using the estimated populational data of 2019 available at the Statistical and Geographical Brazilian Institute for each of the Brazilian states and the federal district (https://datasus.saude.gov.br/populacao-residente/). In order to represent the mortality of COVID-19 , we used classification into deciles. ArcMap 10 .3?was used to generate the map representation.

    Ethical considerations

    The study was approved by the GEDIIB ethical review board under the protocol No.002 /2020 on October 28 , 2020 . Informed consent was waived because the survey recruitment was self-selective. In addition, data were de-identified. Individual participant data were not published, which maintained confidentiality in all steps of study analysis. This study was conducted in compliance with regulations stated in the 1975 Declaration of Helsinki.

    RESULTS

    A total of 3568 IBD patients participated in the national web-based survey and had data included. Six patients were excluded from the analysis due to inconsistent reported data. Overall demographic and baseline characteristics of respondents are illustrated in Table 2 . Most respondents (55 .6 %) were 20 -39 -years-old, and 65 .3 % were females. Current smoking status was reported by 5 .1 % of the participants. The states with the highest response rates to the survey were S?o Paulo (29 .6 %), Rio de Janeiro(9 .4 %) Santa Catarina (7 .7 %), Paraná (7 .7 %), Bahia (6 .0 %) and the Federal District(5 .3 %). Details of the distribution of respondents per state are described in Supplementary Table 2 .

    The proportion of patients presenting with at least one self-reported comorbidity was 21 .6 %, and the most prevalent was hypertension (11 .3 %) followed by chronic pulmonary disease (4 .6 %) and recent (< 30 d) IBD-related abdominal surgery (3 .8 %).Most patients (84 .1 %) were on immune-mediated therapy (biologics 51 .3 % and/or immunomodulators 32 .8 %), 34 .2 % of respondents were using aminosalicylates and 13 .3 % had been recently treated with corticosteroids. Demographic, clinical and treatment characteristics by states is presented in Tables 3 and 4 . The uptake of biological therapy was slightly higher among patients from the southeastern (52 .9 %)and southern (52 .2 %) regions compared with those from the northern region (33 .3 %).Demographic, clinical and treatment characteristics by regions are described in detail in Supplementary Table 3 .

    Overall, the majority (55 .1 %) of patients were at moderate risk, 23 .4 % were at highest risk and 21 .5 % were at lowest risk of developing COVID-19 complications. The proportion of IBD patients at highest, moderate and lowest risk for each state is represented in Figure 1 A-C and for each county/city in Supplementary Figure 1 .Thirteen states had higher proportional rates of patients at highest risk than the national median cutoff of 22 .1 % (Amapá, Rio Grande do Norte, Rio de Janeiro, S?o Paulo, Paraná, Amapá, Federal District, Santa Catarina, Ceará, Goiás, Espírito Santo,Acre and Paraíba). Paraíba was the state with the greatest proportion of IBD patients at highest risk (44 .4 %), followed by Acre (37 .5 %), Espírito Santo (29 .9 %) and Goiás(28 .6 %).

    Geographical distribution of cumulative deaths from COVID-19 in Brazil as of June 2 , 2020 by state (per 100000 people) is represented in Figure 1 D. The national mortality

    rate median cutoff in June 2 was 9 .7 /100000 . The 13 states with mortality rates above the national median were Rio Grande do Norte, Maranh?o, Alagoas, Espírito Santo,S?o Paulo, Acre, Roraima, Amapá, Pernambuco, Rio de Janeiro, Pará, Ceará and Amazonas. The states with higher mortality rates were Amazonas (50 .7 ), Ceará (37 .5 ),Pará (35 .3 ), Rio de Janeiro (32 .9 ) and Amapá (28 ).

    Table 2 Demographic, clinical and treatment characteristics from the whole sample of patients

    When crossing overall proportion of highest risk patients with cumulative mortality rates, the Spearman rank correlation coefficient was not statistically significant (r =0 .146 , P = 0 .467 ). These data are illustrated in Figure 2 .

    DISCUSSION

    This web-based survey analyzed important patient and treatment characteristics that could influence the IBD-related risk of having COVID-19 complications at a national level. Brazil is a continental country with different socioeconomic realities between its five different geographic regions (i.e. Northern, Northeastern, Southern, Southeastern and Midwestern). Most patients who participated in the survey were from the southeastern (n = 1886 ) and southern (n = 738 ) regions, which are more developed areas of the country. This may reflect patients who more often follow official mailing lists from the study group (as the call for participation in the survey) and might be treated in IBD tertiary referral centers. This could also mirror a higher prevalence of IBD in these regions of Brazil as compared to others as stated in a systematic review and some population-based studies[7-10]. Indeed, the findings of our study may not reflect a full national reality, as patients from the northern and northeastern regions may have a different IBD treatment profile. In the same line, it is noteworthy that the northern region had the highest proportion of patients with no current IBD medication(17 .6 %), and the southern and southeastern regions the highest proportion of patients under biological therapy (52 .2 % and 52 .9 %, respectively).

    Our study suggests a different geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country, which may reflect different socioeconomic, educational and healthcare issues that could potentially have affected our findings. Despite the fact that the states of Paraíba, Acre, Espírito Santo and Goiás had the greatest proportion of patients at highest risk, this was not reflected in higher COVID-related mortality according to official data from the Ministry of Health. Higher mortality for COVID-19 as of June 2 , 2020 (last available date capturing responses in the survey) was observed in the states of Amazonas, Ceará and Rio de Janeiro.

    Nevertheless, a clear correlation between the risk of COVID-19 complications in IBD patients and mortality was not demonstrated according to the Spearman test. This important finding is in tune with other previously published data from IBD cohorts,which did not identify worse COVID-19 disease courses in IBD patients[3 ,11]. This analysis underscores the important finding that the majority of respondents (55 .1 %)were classified at moderate risk, which means that they were currently having adequate IBD treatment with no increased rates of steroid therapy. Despite being treated with immunosuppressant agents, this population may not be as vulnerable as expected[12]. Although this still needs to be proven, speculation is undertaken if the reduction of the COVID-related “cytokine storm” can be achieved with adequate medical therapy for IBD[13]. More studies in this field are warranted. It is important to state that no longitudinal follow-up of these patients was evaluated in this study. The exact number of infected patients with IBD within our sample was out of the focus of the survey.

    When data is analyzed by regions, the proportion of IBD patients at highest risk was 20 %-25 %, and the majority of patients comprised those using immunomodulators or biologics with no active disease, did not undergo recent IBD-related surgery and were not under steroid therapy. This may reinforce the fact that the survey reached more patients who were likely under regular follow-up with their specialists, a common practice in more developed areas. Another important point is that no significant difference between the regions in the low, moderate or high risk of COVID-related complications was demonstrated (P = 0 .118 ; Supplementary Table 2 ). This may also be demonstrated by the fact that even in the same region, a particular state could have adifferent frequency of high risk in comparison to its neighbors. As an example, the proportion of patients at highest risk was 28 .6 % in the state of Goiás and only 14 .3 % in Tocantins and 16 .7 % in Mato Grosso do Sul, all states from the midwestern region.This can also be justified by different types of IBD care and patient profiles in terms of comorbidities between the states, which demonstrates the complexity of analyzing data in a heterogeneous country such as Brazil.

    Table 3 Demographic, clinical and treatment characteristics by states in Brazil

    1 Monotherapy indicates no concomitant biologics or aminosalicylates/6 -mercaptopurine/methotrexate.2 These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.3 Combo therapy refers to biologics plus aminosalicylates/6 -mercaptopurine/methotrexate.5 -ASA: Aminosalicylates; AZA: Azathioprine; 6 -MP: 6 -Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.

    Regarding COVID-related mortality rates in Brazil, it seems clear that the higher rates found in the states of Amazonas, Ceará, Pará, Rio de Janeiro and Amapá reflect difficulties in healthcare in these specific areas. Most of these states belong to less developed regions of the country (northern and northeastern). These are states with chronic difficulties in the public health system over the last decades, with limited resources, reduced numbers of hospitals and consequently disproportional intensive care unit beds per 100000 inhabitants[14 ]. Recent data revealed that Brazil has 15 .6 intensive care unit beds per 100000 inhabitants. Considering only intensive care unit beds from the public health system, the average drops to 7 .1 per 100000 inhabitants,and there are significant differences between the regions of the country. Among the population exclusively dependent on the public health system, 30 .5 % of the Northeast,22 .6 % of the North and 21 % of the Midwest regions live in places without intensive care unit beds[15].

    Socioeconomical limitations may also be illustrated by the assessment of the Human Development Index (HDI) in these states because it is based on three aspects: Health,as measured by life expectancy at birth; Knowledge, as measured by the adult literacy rate; and A decent standard of living, as measured by gross domestic product per capita. Concerning the five geographic regions of Brazil, the first five states with the highest HDI are from the South, Southeast and Midwest regions and the last five states with the lowest HDI are from the North and Northeast regions[16]. Despite the northern and northeastern regions having a lower prevalence of IBD patients, the significant percentage of patients at highest risk for COVID-19 complications might reflect a similar healthcare system limitation, possibly with few available IBD specialists in therespective regions.

    Table 4 Demographic, clinical and treatment characteristics by states in Brazil (continuation of Table 3 )

    1 Monotherapy indicates no concomitant biologics or aminosalicylates/6 -mercaptopurine/methotrexate.2 These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.3 Combo therapy refers to biologics plus aminosalicylates/6 -mercaptopurine/methotrexate.5 -ASA: Aminosalicylates; AZA: Azathioprine; 6 -MP: 6 -Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.

    It is not being an easy task for Brazilian health authorities to deal with the COVID-19 pandemic. The country is facing important economic and political challenges that likely contribute to the significant increase of the number of cases and deaths throughout the country. The Brazilian government has been a recurrent target for scientific and regular media worldwide[17]. We truly hope this manuscript can raise awareness and call the attention from national health authorities with respect to vulnerability of specific populations during this critical period our country is facing.

    The present study is associated with some limitations, which must be considered for adequate interpretation of the results. First, as previously mentioned, the higher proportion of respondents coming from the southeastern and southern regions may not reflect the reality in other states, mostly from the northern and northeastern regions, which have more rural areas and lower HDI. Another important point is that the survey was simple, objective and analyzed a limited number of variables. As an example, even the simple diagnostic difference between ulcerative colitis and Crohn’s disease was not evaluated. Disease activity at the time of the survey was not captured,which could have influenced the results. Data is also derived from self-reported personal and treatment-related characteristics, which may be biased by individual intellectual issues. Important additional limitations of our study include the absence of follow-up of the patients who replied to the survey. By not having this information,we could not describe in detail if patients who had COVID-19 infection continued their medications, possible differences between ulcerative colitis and Crohn’s disease or common manifestations of severe acute respiratory syndrome coronavirus-2 among included patients due to methodological issues. Despite these limitations, the study’s strength is based in the large number of patients who responded to the survey from all states of Brazil, and this represents one of the largest databases regarding COVID-19 risk for complications in IBD patients globally.

    Figure 1 Inflammatory bowel disease patients at low, moderate and high risk for complications of coronavirus disease 2019 and coronavirus disease-related deaths in Brazil by state (per 100000 people). A: Low risk; B: Moderate risk; C: High risk; D: Coronavirus disease 2019 deaths. COVID: Coronavirus disease; IBD: Inflammatory bowel disease.

    CONCLUSION

    In summary, no correlation between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified among Brazilian states. This can be related to the fact that the majority of the IBD patients are at moderate risk, which could possibly reflect adequate treatment and controlled disease.More epidemiological data comparing IBD and COVID-19 outcomes are suggested in large countries such as Brazil to properly position which IBD patients are more vulnerable in this pandemic period.

    Figure 2 Spearman correlation test between the 27 states and cumulative coronavirus disease 2019 mortality rates. No significant correlation was identified (r = 0 .146 , P = 0 .467 ). COVID-19 : Coronavirus disease 2019 ; IBD: Inflammatory bowel disease.

    ARTICLE HIGHLIGHTS

    亚洲精品av麻豆狂野| √禁漫天堂资源中文www| 国产精品秋霞免费鲁丝片| 国产欧美日韩一区二区精品| 精品久久久久久久久久免费视频| 少妇 在线观看| 99国产极品粉嫩在线观看| 久久中文看片网| 嫩草影院精品99| 中文字幕人妻熟女乱码| 免费观看精品视频网站| ponron亚洲| 色综合亚洲欧美另类图片| 变态另类丝袜制服| a在线观看视频网站| 久久久久久久精品吃奶| www国产在线视频色| 国产成人精品久久二区二区免费| 日韩精品青青久久久久久| 亚洲av成人av| 亚洲国产欧美一区二区综合| 可以在线观看的亚洲视频| 黄色a级毛片大全视频| 国产精品免费视频内射| 日韩精品免费视频一区二区三区| 色播亚洲综合网| 精品一区二区三区四区五区乱码| 欧美乱码精品一区二区三区| 无遮挡黄片免费观看| 国产精品爽爽va在线观看网站 | 色综合站精品国产| 热99re8久久精品国产| 国产精品电影一区二区三区| www.自偷自拍.com| 欧美日韩亚洲综合一区二区三区_| 欧美色视频一区免费| 久久人人爽av亚洲精品天堂| 午夜精品国产一区二区电影| 两个人免费观看高清视频| 少妇裸体淫交视频免费看高清 | 亚洲狠狠婷婷综合久久图片| 18禁黄网站禁片午夜丰满| 国产99久久九九免费精品| 亚洲精品在线美女| 久久精品国产清高在天天线| 如日韩欧美国产精品一区二区三区| 黄色丝袜av网址大全| 国产精品一区二区精品视频观看| 1024香蕉在线观看| 国产熟女午夜一区二区三区| 9191精品国产免费久久| 国产成人系列免费观看| 少妇裸体淫交视频免费看高清 | 免费观看人在逋| 亚洲免费av在线视频| 国产熟女xx| 女人高潮潮喷娇喘18禁视频| 亚洲av熟女| 婷婷丁香在线五月| 又紧又爽又黄一区二区| 男女下面进入的视频免费午夜 | 午夜精品在线福利| 国产1区2区3区精品| 999久久久精品免费观看国产| 欧美激情 高清一区二区三区| 国产精品久久视频播放| 高潮久久久久久久久久久不卡| 久久久久久免费高清国产稀缺| 亚洲视频免费观看视频| 麻豆国产av国片精品| 日韩大尺度精品在线看网址 | 最新在线观看一区二区三区| 亚洲午夜精品一区,二区,三区| 久久国产精品男人的天堂亚洲| 51午夜福利影视在线观看| 久久久久久亚洲精品国产蜜桃av| 成人国产综合亚洲| 精品乱码久久久久久99久播| 欧美成人性av电影在线观看| 中文字幕色久视频| 侵犯人妻中文字幕一二三四区| 中文字幕人成人乱码亚洲影| 亚洲精品久久国产高清桃花| 怎么达到女性高潮| 亚洲伊人色综图| 成在线人永久免费视频| 成年人黄色毛片网站| 日韩大尺度精品在线看网址 | 婷婷丁香在线五月| 国产乱人伦免费视频| 欧美黑人精品巨大| 国产成人影院久久av| 91大片在线观看| 亚洲午夜精品一区,二区,三区| 午夜a级毛片| 一级片免费观看大全| 日本三级黄在线观看| 黄色成人免费大全| 国产黄a三级三级三级人| 精品熟女少妇八av免费久了| 午夜福利影视在线免费观看| 国产av一区二区精品久久| 又大又爽又粗| 一级毛片精品| 久久国产精品男人的天堂亚洲| 亚洲国产精品成人综合色| 国产精华一区二区三区| 在线国产一区二区在线| 国产精品香港三级国产av潘金莲| 如日韩欧美国产精品一区二区三区| 看免费av毛片| 亚洲国产精品sss在线观看| 日本a在线网址| 免费久久久久久久精品成人欧美视频| 国产视频一区二区在线看| 88av欧美| 十分钟在线观看高清视频www| 99国产精品一区二区三区| 久久狼人影院| 亚洲色图 男人天堂 中文字幕| 怎么达到女性高潮| 欧美av亚洲av综合av国产av| 亚洲中文av在线| 欧美色欧美亚洲另类二区 | 丝袜人妻中文字幕| 亚洲精品一区av在线观看| 欧美激情极品国产一区二区三区| 久久久久国产一级毛片高清牌| 亚洲色图av天堂| 精品乱码久久久久久99久播| 两人在一起打扑克的视频| 99国产精品一区二区三区| 两个人免费观看高清视频| 午夜福利视频1000在线观看 | 亚洲av第一区精品v没综合| 亚洲国产中文字幕在线视频| 亚洲欧美精品综合一区二区三区| 久久久久久国产a免费观看| 操美女的视频在线观看| 国产精品亚洲一级av第二区| 免费高清在线观看日韩| 国内久久婷婷六月综合欲色啪| 精品国产亚洲在线| 久久中文字幕人妻熟女| 国产日韩一区二区三区精品不卡| 国产精品久久久久久亚洲av鲁大| 亚洲欧美一区二区三区黑人| 人妻丰满熟妇av一区二区三区| 91字幕亚洲| 女性生殖器流出的白浆| 国产亚洲欧美精品永久| 成人特级黄色片久久久久久久| 欧美激情极品国产一区二区三区| www.精华液| 在线观看www视频免费| 国产精品日韩av在线免费观看 | 他把我摸到了高潮在线观看| 操美女的视频在线观看| 夜夜看夜夜爽夜夜摸| 国产精品日韩av在线免费观看 | 日韩欧美三级三区| 夜夜夜夜夜久久久久| 日韩精品中文字幕看吧| 女生性感内裤真人,穿戴方法视频| 亚洲人成伊人成综合网2020| 精品不卡国产一区二区三区| 国产精品精品国产色婷婷| 国产激情久久老熟女| 黄网站色视频无遮挡免费观看| 成人免费观看视频高清| 色尼玛亚洲综合影院| 久久久久久免费高清国产稀缺| 国产精品爽爽va在线观看网站 | 亚洲欧美日韩高清在线视频| 国产亚洲精品第一综合不卡| 99riav亚洲国产免费| 国产1区2区3区精品| 国产真人三级小视频在线观看| 嫁个100分男人电影在线观看| 99国产精品99久久久久| 日韩精品免费视频一区二区三区| 热99re8久久精品国产| 久久久久国产精品人妻aⅴ院| 欧美激情 高清一区二区三区| 国产国语露脸激情在线看| 在线十欧美十亚洲十日本专区| 一区福利在线观看| 精品无人区乱码1区二区| 成人国产综合亚洲| or卡值多少钱| 9色porny在线观看| 国产精品久久久av美女十八| 久久午夜亚洲精品久久| 亚洲av五月六月丁香网| 成人亚洲精品一区在线观看| 久久影院123| 大型黄色视频在线免费观看| 久久精品成人免费网站| 一本大道久久a久久精品| 亚洲视频免费观看视频| 99久久综合精品五月天人人| 亚洲全国av大片| 最近最新中文字幕大全免费视频| 久久久久久久久中文| 国产精品久久久av美女十八| 久久香蕉激情| 777久久人妻少妇嫩草av网站| 亚洲视频免费观看视频| 99久久综合精品五月天人人| 久久欧美精品欧美久久欧美| 亚洲五月婷婷丁香| 日韩精品中文字幕看吧| 久久香蕉国产精品| 法律面前人人平等表现在哪些方面| 动漫黄色视频在线观看| 母亲3免费完整高清在线观看| 成人18禁高潮啪啪吃奶动态图| 丝袜在线中文字幕| 久久久久久久精品吃奶| 在线观看舔阴道视频| 久久国产精品男人的天堂亚洲| 欧美色视频一区免费| 两性午夜刺激爽爽歪歪视频在线观看 | 黄色视频,在线免费观看| 亚洲成a人片在线一区二区| 中文亚洲av片在线观看爽| 国产av精品麻豆| 国产aⅴ精品一区二区三区波| 99久久久亚洲精品蜜臀av| 国产高清有码在线观看视频 | 可以在线观看的亚洲视频| 老司机在亚洲福利影院| av有码第一页| 国产片内射在线| 乱人伦中国视频| 久久久久九九精品影院| 岛国在线观看网站| 俄罗斯特黄特色一大片| 国产激情欧美一区二区| 婷婷六月久久综合丁香| 国产成人欧美在线观看| 国产精品影院久久| 亚洲色图 男人天堂 中文字幕| 国产精品国产高清国产av| 国产三级黄色录像| 国内久久婷婷六月综合欲色啪| av天堂在线播放| 黄片大片在线免费观看| 精品福利观看| 亚洲七黄色美女视频| 窝窝影院91人妻| 少妇被粗大的猛进出69影院| 久9热在线精品视频| 免费无遮挡裸体视频| 色综合站精品国产| 免费观看精品视频网站| 亚洲av美国av| 黄色丝袜av网址大全| 91成人精品电影| a级毛片在线看网站| 国产亚洲精品av在线| 88av欧美| 国产aⅴ精品一区二区三区波| 免费少妇av软件| 18美女黄网站色大片免费观看| 看片在线看免费视频| 欧美日本亚洲视频在线播放| 欧美乱妇无乱码| 岛国在线观看网站| 麻豆久久精品国产亚洲av| 黄色视频不卡| 夜夜躁狠狠躁天天躁| av欧美777| av片东京热男人的天堂| www.自偷自拍.com| 国产欧美日韩综合在线一区二区| 亚洲一区二区三区色噜噜| av有码第一页| 国内精品久久久久精免费| 日韩精品免费视频一区二区三区| 女人精品久久久久毛片| 日韩精品青青久久久久久| 成人手机av| 两性午夜刺激爽爽歪歪视频在线观看 | 国产精品98久久久久久宅男小说| 国产高清有码在线观看视频 | 亚洲一卡2卡3卡4卡5卡精品中文| 妹子高潮喷水视频| www.www免费av| 女性被躁到高潮视频| 久久久精品欧美日韩精品| 啦啦啦观看免费观看视频高清 | 日日爽夜夜爽网站| 国产精品久久久久久精品电影 | 国产麻豆成人av免费视频| 好男人在线观看高清免费视频 | 天天躁狠狠躁夜夜躁狠狠躁| 免费少妇av软件| 搡老妇女老女人老熟妇| 搡老熟女国产l中国老女人| 亚洲精品美女久久久久99蜜臀| 欧美一级毛片孕妇| 中文亚洲av片在线观看爽| 人成视频在线观看免费观看| 一边摸一边抽搐一进一出视频| 日韩欧美国产一区二区入口| av福利片在线| 纯流量卡能插随身wifi吗| 大香蕉久久成人网| 看免费av毛片| 日韩精品青青久久久久久| 欧美色视频一区免费| 久久香蕉精品热| 一个人免费在线观看的高清视频| 久久久久久久久中文| 欧美日本中文国产一区发布| 黄片播放在线免费| 88av欧美| 精品国产乱子伦一区二区三区| 丰满的人妻完整版| 亚洲avbb在线观看| 一级黄色大片毛片| 人成视频在线观看免费观看| 韩国av一区二区三区四区| 成人免费观看视频高清| 久久久久久久久中文| 久久久水蜜桃国产精品网| 久久影院123| 国产蜜桃级精品一区二区三区| 精品日产1卡2卡| 亚洲成人久久性| 给我免费播放毛片高清在线观看| 美女国产高潮福利片在线看| 男女下面插进去视频免费观看| 久久精品亚洲精品国产色婷小说| 午夜亚洲福利在线播放| 99久久99久久久精品蜜桃| 亚洲熟妇熟女久久| 免费在线观看日本一区| 99在线人妻在线中文字幕| 亚洲在线自拍视频| 国产私拍福利视频在线观看| 久久影院123| 免费av毛片视频| 午夜久久久在线观看| 亚洲第一av免费看| 三级毛片av免费| 男人舔女人的私密视频| 三级毛片av免费| 亚洲一区二区三区色噜噜| 成人手机av| 亚洲 欧美 日韩 在线 免费| 国产色视频综合| 超碰成人久久| 69av精品久久久久久| www日本在线高清视频| 国产伦人伦偷精品视频| 又黄又爽又免费观看的视频| 免费人成视频x8x8入口观看| 免费一级毛片在线播放高清视频 | 91在线观看av| 国产亚洲精品久久久久5区| 国产亚洲精品一区二区www| av有码第一页| 亚洲国产日韩欧美精品在线观看 | 精品人妻在线不人妻| 国产精品美女特级片免费视频播放器 | 日日干狠狠操夜夜爽| 一本大道久久a久久精品| 精品国产乱码久久久久久男人| 在线国产一区二区在线| 国产一区二区三区综合在线观看| 久久国产亚洲av麻豆专区| av有码第一页| 国产熟女xx| 中文字幕另类日韩欧美亚洲嫩草| 在线十欧美十亚洲十日本专区| а√天堂www在线а√下载| 国产免费男女视频| 黄色视频,在线免费观看| 午夜日韩欧美国产| 日韩欧美免费精品| 欧美乱码精品一区二区三区| 侵犯人妻中文字幕一二三四区| 超碰成人久久| videosex国产| 国产亚洲精品一区二区www| or卡值多少钱| 一本大道久久a久久精品| 男女之事视频高清在线观看| 老司机在亚洲福利影院| 国产精品久久视频播放| 久久久久久免费高清国产稀缺| 天堂√8在线中文| 精品国产乱子伦一区二区三区| 老汉色av国产亚洲站长工具| 亚洲第一电影网av| 宅男免费午夜| 国产精品电影一区二区三区| 日韩视频一区二区在线观看| 精品久久久精品久久久| 男女下面插进去视频免费观看| 日韩国内少妇激情av| 成在线人永久免费视频| 又黄又爽又免费观看的视频| www.www免费av| 国产99白浆流出| 中文字幕人妻熟女乱码| 最好的美女福利视频网| 黄色视频,在线免费观看| 国产精品电影一区二区三区| 天堂√8在线中文| 中文字幕高清在线视频| 丝袜美腿诱惑在线| 无限看片的www在线观看| av视频在线观看入口| 国产精品国产高清国产av| 一级,二级,三级黄色视频| 午夜两性在线视频| 久99久视频精品免费| 国产精品久久久久久亚洲av鲁大| 99久久综合精品五月天人人| 一进一出好大好爽视频| 99精品在免费线老司机午夜| 叶爱在线成人免费视频播放| 国产精品国产高清国产av| 18美女黄网站色大片免费观看| 亚洲 欧美 日韩 在线 免费| 国产麻豆成人av免费视频| 国产精品一区二区在线不卡| 日韩三级视频一区二区三区| 亚洲天堂国产精品一区在线| 国产男靠女视频免费网站| 中文字幕色久视频| av欧美777| 最新美女视频免费是黄的| 欧美日本中文国产一区发布| 国产亚洲精品一区二区www| 满18在线观看网站| 色老头精品视频在线观看| 一边摸一边抽搐一进一小说| ponron亚洲| 国产97色在线日韩免费| 欧美黑人精品巨大| 午夜免费鲁丝| 亚洲九九香蕉| 午夜激情av网站| 久久精品成人免费网站| 亚洲欧美日韩另类电影网站| 日韩有码中文字幕| 丁香欧美五月| 午夜精品久久久久久毛片777| 波多野结衣高清无吗| 最新在线观看一区二区三区| 少妇被粗大的猛进出69影院| 中文字幕av电影在线播放| 久久人妻福利社区极品人妻图片| 国产精品1区2区在线观看.| 在线观看免费日韩欧美大片| 嫩草影视91久久| www国产在线视频色| 日韩精品免费视频一区二区三区| 国产成人av激情在线播放| 90打野战视频偷拍视频| 亚洲午夜精品一区,二区,三区| 午夜免费激情av| 国产欧美日韩一区二区三区在线| 国产单亲对白刺激| 国产私拍福利视频在线观看| 国产成人精品久久二区二区免费| 免费人成视频x8x8入口观看| 国产午夜福利久久久久久| 国产成人影院久久av| 日本免费一区二区三区高清不卡 | 亚洲电影在线观看av| 又大又爽又粗| 黑人巨大精品欧美一区二区蜜桃| 午夜精品在线福利| 人人妻人人澡欧美一区二区 | 久久久久久人人人人人| 国产av又大| 男女午夜视频在线观看| 正在播放国产对白刺激| 亚洲无线在线观看| 激情在线观看视频在线高清| 好男人在线观看高清免费视频 | 欧美日韩乱码在线| 午夜两性在线视频| aaaaa片日本免费| 999精品在线视频| 亚洲成a人片在线一区二区| 国产高清激情床上av| 精品国内亚洲2022精品成人| 国内毛片毛片毛片毛片毛片| 亚洲欧美激情在线| 日本vs欧美在线观看视频| 日韩欧美一区视频在线观看| 丁香六月欧美| 亚洲一码二码三码区别大吗| 国产视频一区二区在线看| 国产成人av教育| 日韩 欧美 亚洲 中文字幕| 91老司机精品| 欧美激情高清一区二区三区| 亚洲三区欧美一区| 97超级碰碰碰精品色视频在线观看| 欧美黑人精品巨大| 看片在线看免费视频| 高清黄色对白视频在线免费看| 国产一级毛片七仙女欲春2 | 美国免费a级毛片| 午夜福利一区二区在线看| 日日夜夜操网爽| 日日干狠狠操夜夜爽| 国产一区二区三区视频了| 亚洲一区高清亚洲精品| 国产一卡二卡三卡精品| 男男h啪啪无遮挡| 亚洲人成77777在线视频| 777久久人妻少妇嫩草av网站| 亚洲人成电影免费在线| 一区福利在线观看| 国产99久久九九免费精品| 亚洲欧美一区二区三区黑人| 久久精品91蜜桃| 国产精品秋霞免费鲁丝片| 日韩精品青青久久久久久| 亚洲av电影不卡..在线观看| 99在线人妻在线中文字幕| 欧美精品啪啪一区二区三区| 欧美人与性动交α欧美精品济南到| 亚洲第一av免费看| 免费在线观看日本一区| 久久久久久久精品吃奶| 身体一侧抽搐| 中文字幕人妻熟女乱码| 妹子高潮喷水视频| 大码成人一级视频| 在线天堂中文资源库| 亚洲国产精品合色在线| 色精品久久人妻99蜜桃| 欧美+亚洲+日韩+国产| 久久伊人香网站| 91成年电影在线观看| 黄色成人免费大全| 亚洲人成伊人成综合网2020| avwww免费| 国产激情欧美一区二区| 一级片免费观看大全| www.自偷自拍.com| 级片在线观看| 精品国产乱码久久久久久男人| 亚洲精品一卡2卡三卡4卡5卡| 精品无人区乱码1区二区| 久久天堂一区二区三区四区| 亚洲一区二区三区不卡视频| 黄片大片在线免费观看| 国产成人系列免费观看| 亚洲色图综合在线观看| 久久久久久久精品吃奶| 97碰自拍视频| 久久影院123| 中文字幕另类日韩欧美亚洲嫩草| 999久久久精品免费观看国产| 欧美一级毛片孕妇| 啦啦啦 在线观看视频| 欧美日韩精品网址| 美女 人体艺术 gogo| 国产91精品成人一区二区三区| 亚洲一区二区三区不卡视频| 真人一进一出gif抽搐免费| 巨乳人妻的诱惑在线观看| 免费在线观看日本一区| 母亲3免费完整高清在线观看| 黑人巨大精品欧美一区二区蜜桃| 欧美大码av| 国产亚洲精品久久久久5区| 12—13女人毛片做爰片一| 国产精品久久电影中文字幕| 亚洲av日韩精品久久久久久密| 在线观看免费视频日本深夜| 亚洲成a人片在线一区二区| 中文字幕人妻丝袜一区二区| 少妇熟女aⅴ在线视频| 日本一区二区免费在线视频| 少妇被粗大的猛进出69影院| 国产成+人综合+亚洲专区| 好男人在线观看高清免费视频 | 母亲3免费完整高清在线观看| 日韩欧美国产一区二区入口| 久久人妻av系列| 高清黄色对白视频在线免费看| 天天躁夜夜躁狠狠躁躁| 中文字幕最新亚洲高清| 黄频高清免费视频| 精品电影一区二区在线| 制服人妻中文乱码| 搡老妇女老女人老熟妇| 天天躁夜夜躁狠狠躁躁| 久久影院123| 亚洲精品中文字幕一二三四区| 纯流量卡能插随身wifi吗| 国产av一区在线观看免费| 日本免费a在线| 男人舔女人的私密视频| 久久午夜综合久久蜜桃| 亚洲av熟女| 婷婷精品国产亚洲av在线| 淫妇啪啪啪对白视频| 中文字幕人妻丝袜一区二区| 成年版毛片免费区| 成年人黄色毛片网站| avwww免费| 成人永久免费在线观看视频| 99精品久久久久人妻精品|